PubRank

Paola Neri

Author PubWeight™ 38.24‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006 2.24
2 HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2004 1.95
3 MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res 2006 1.75
4 Dysfunctional T regulatory cells in multiple myeloma. Blood 2005 1.72
5 Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2006 1.62
6 A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 2005 1.60
7 Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood 2006 1.56
8 Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol Ther 2009 1.32
9 Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 2004 1.31
10 Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol 2007 1.26
11 Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood 2006 1.21
12 Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood 2008 1.18
13 A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res 2005 1.15
14 Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin Cancer Res 2005 1.09
15 Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. Mol Cancer Ther 2009 1.00
16 p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol 2008 0.96
17 Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood 2005 0.95
18 Reovirus as a viable therapeutic option for the treatment of multiple myeloma. Clin Cancer Res 2012 0.95
19 Watch how to do it! New advances in learning by observation. Brain Res Brain Res Rev 2003 0.94
20 In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer. Cancer Chemother Pharmacol 2009 0.94
21 Reovirus modulates autophagy during oncolysis of multiple myeloma. Autophagy 2013 0.89
22 A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2. Vaccine 2008 0.85
23 A SCID-hu in vivo model of human Waldenström macroglobulinemia. Blood 2005 0.83
24 Protection of mice from Shiga toxin-2 toxemia by mucosal vaccine of Shiga toxin 2B-His with Escherichia coli enterotoxin. Vaccine 2007 0.83
25 Localized surface plasmon resonance detection of biological toxins using cell surface oligosaccharides on glyco chips. ACS Appl Mater Interfaces 2013 0.81
26 Evaluation of a new enzymatic method for homocysteine measurement. Clin Biochem 2005 0.81
27 Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model. Exp Hematol 2007 0.80
28 NMDA receptor activity in learning spatial procedural strategies I. The influence of hippocampal lesions. Brain Res Bull 2006 0.80
29 NMDA receptor activity in learning spatial procedural strategies II. The influence of cerebellar lesions. Brain Res Bull 2006 0.78
30 A new paradigm to analyze observational learning in rats. Brain Res Brain Res Protoc 2003 0.78
31 Inhibitory mechanism of 10-hydroxy-trans-2-decenoic acid (royal jelly acid) against lipopolysaccharide- and interferon-β-induced nitric oxide production. Inflammation 2013 0.77
32 Inhibition of interferon-γ-induced nitric oxide production by 10-hydroxy-trans-2-decenoic acid through inhibition of interferon regulatory factor-8 induction. Cell Immunol 2011 0.77
33 Inhibitory effect of 10-hydroxy-trans-2-decenoic acid on LPS-induced IL-6 production via reducing IκB-ζ expression. Innate Immun 2011 0.76
34 Glycochips from polyanionic glycopolymers as tools for detecting Shiga toxins. Chembiochem 2007 0.76
35 Multivalent galacto-trehaloses: design, synthesis, and biological evaluation under the concept of carbohydrate modules. Biomacromolecules 2009 0.76
36 Mechanism of inhibition of lipopolysaccharide-induced interferon-β production by 2-aminopurine. Mol Immunol 2012 0.76
37 Analytical evaluation of a new immunonephelometric method for homocysteine measurement. Clin Chim Acta 2006 0.75